254 related articles for article (PubMed ID: 30944610)
1. Tumor infiltrating lymphocytes: The regulator of melanoma evolution.
Antohe M; Nedelcu RI; Nichita L; Popp CG; Cioplea M; Brinzea A; Hodorogea A; Calinescu A; Balaban M; Ion DA; Diaconu C; Bleotu C; Pirici D; Zurac SA; Turcu G
Oncol Lett; 2019 May; 17(5):4155-4161. PubMed ID: 30944610
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.
Lee N; Zakka LR; Mihm MC; Schatton T
Pathology; 2016 Feb; 48(2):177-87. PubMed ID: 27020390
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.
Ladányi A
Pigment Cell Melanoma Res; 2015 Sep; 28(5):490-500. PubMed ID: 25818762
[TBL] [Abstract][Full Text] [Related]
4. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of tumor-infiltrating immune cells in melanoma].
Ladányi A
Magy Onkol; 2013 Jun; 57(2):85-95. PubMed ID: 23795353
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma.
Vargas GM; Shafique N; Xu X; Karakousis G
Expert Rev Mol Diagn; 2024 Apr; 24(4):299-310. PubMed ID: 38314660
[TBL] [Abstract][Full Text] [Related]
7. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.
Schatton T; Scolyer RA; Thompson JF; Mihm MC
Methods Mol Biol; 2014; 1102():287-324. PubMed ID: 24258985
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
10. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
11. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
12. Antigen-Presenting Intratumoral B Cells Affect CD4
Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
15. Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.
Kotlan B; Horvath S; Eles K; Plotar VK; Naszados G; Czirbesz K; Blank M; Farkas E; Toth L; Tovari J; Szekacs A; Shoenfeld Y; Godeny M; Kasler M; Liszkay G
Front Immunol; 2019; 10():650. PubMed ID: 31024530
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.
Kelderman S; Heemskerk B; Fanchi L; Philips D; Toebes M; Kvistborg P; van Buuren MM; van Rooij N; Michels S; Germeroth L; Haanen JB; Schumacher NM
Eur J Immunol; 2016 Jun; 46(6):1351-60. PubMed ID: 27005018
[TBL] [Abstract][Full Text] [Related]
18. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
19. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma.
Bronkhorst IH; Vu TH; Jordanova ES; Luyten GP; Burg SH; Jager MJ
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5370-8. PubMed ID: 22743317
[TBL] [Abstract][Full Text] [Related]
20. Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
Iacono D; Cinausero M; Gerratana L; Angione V; Scott CA; De Maglio G; Pizzolitto S; Di Loreto C; Puglisi F; Fasola G; Minisini AM
Melanoma Res; 2018 Dec; 28(6):547-554. PubMed ID: 29794562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
